News
Apogee rises as long-acting eczema drug heads for phase 3 Apogee's chief executive Michael Henderson.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback